These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 32122374)

  • 1. Metabolism of pancreatic cancer: paving the way to better anticancer strategies.
    Qin C; Yang G; Yang J; Ren B; Wang H; Chen G; Zhao F; You L; Wang W; Zhao Y
    Mol Cancer; 2020 Mar; 19(1):50. PubMed ID: 32122374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.
    Swierczynski J; Hebanowska A; Sledzinski T
    World J Gastroenterol; 2014 Mar; 20(9):2279-303. PubMed ID: 24605027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance in pancreatic cancer: Impact of altered energy metabolism.
    Grasso C; Jansen G; Giovannetti E
    Crit Rev Oncol Hematol; 2017 Jun; 114():139-152. PubMed ID: 28477742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy.
    Donadelli M; Dando I; Dalla Pozza E; Palmieri M
    World J Gastroenterol; 2015 Mar; 21(11):3232-8. PubMed ID: 25805929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.
    Vennin C; Murphy KJ; Morton JP; Cox TR; Pajic M; Timpson P
    Gastroenterology; 2018 Mar; 154(4):820-838. PubMed ID: 29287624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology.
    Zhan HX; Zhou B; Cheng YG; Xu JW; Wang L; Zhang GY; Hu SY
    Cancer Lett; 2017 Apr; 392():83-93. PubMed ID: 28189533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
    Halbrook CJ; Lyssiotis CA
    Cancer Cell; 2017 Jan; 31(1):5-19. PubMed ID: 28073003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
    Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological role of metabolic reprogramming of cancer cells during epithelial‑mesenchymal transition (Review).
    Li M; Bu X; Cai B; Liang P; Li K; Qu X; Shen L
    Oncol Rep; 2019 Feb; 41(2):727-741. PubMed ID: 30483813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Bile Acids in Pancreatic Cancer.
    Wang Y; Xu H; Zhang X; Ma J; Xue S; Shentu D; Mao T; Li S; Yue M; Cui J; Wang L
    Curr Cancer Drug Targets; 2024; 24(10):1005-1014. PubMed ID: 38284711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoproteins and glycoproteomics in pancreatic cancer.
    Pan S; Brentnall TA; Chen R
    World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conceptual framework for cutting the pancreatic cancer fuel supply.
    Le A; Rajeshkumar NV; Maitra A; Dang CV
    Clin Cancer Res; 2012 Aug; 18(16):4285-90. PubMed ID: 22896695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells.
    Nomura A; Dauer P; Gupta V; McGinn O; Arora N; Majumdar K; Uhlrich C; Dalluge J; Dudeja V; Saluja A; Banerjee S
    Oncotarget; 2016 Aug; 7(35):56324-56337. PubMed ID: 27472388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment participates in metastasis of pancreatic cancer.
    Ren B; Cui M; Yang G; Wang H; Feng M; You L; Zhao Y
    Mol Cancer; 2018 Jul; 17(1):108. PubMed ID: 30060755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling pancreatic cancer with metronomic chemotherapy.
    Romiti A; Falcone R; Roberto M; Marchetti P
    Cancer Lett; 2017 May; 394():88-95. PubMed ID: 28232048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer: systemic combination therapies for a heterogeneous disease.
    Melisi D; Calvetti L; Frizziero M; Tortora G
    Curr Pharm Des; 2014; 20(42):6660-9. PubMed ID: 25341938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-gene signaling pathways in pancreatic cancer.
    Drakaki A; Iliopoulos D
    Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of cholesterol metabolism reprogramming in pancreatic cancer and the application of cholesterol-targeted metabolism drugs].
    Zhao RL; Li QQ; Liu YS; Zhang J
    Sheng Li Xue Bao; 2023 Jun; 75(3):413-428. PubMed ID: 37340650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.